Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.
ImmuneID, a US-based precision immunology drug developer utilising Harvard University and Johns Hopkins University research, completed a $50m series A round yesterday featuring Harvard-aligned venture capital firm Xfund.
The round was led by Alta Partners and included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as real estate investment manager Redwood Capital Investments, VC firm Section 32 and asset manager Tekla Capital Management.
The round also featured existing backers Arch Venture Partners, Longwood Fund, Pitango HealthTech and In-Q-Tel, the investment vehicle for the US intelligence community.
ImmuneID is working on a technology platform that exploits sequencing, robotic automation and artificial intelligence to identify treatments for conditions linked to the immune system, such as severe allergy, cancer, autoimmune and infectious diseases.
The company will use the funding to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.
Dan Janney, managing partner of Alta Partners, and Section 32 managing partner Steve Kafka will join ImmuneID’s board of directors in conjunction with the round.
This series A brings the total raised by ImmuneID to over $70m. It launched in February 2021 with $17m in seed funding from Longwood Fund, Xfund, Arch Venture Partners, Pitango HealthTech, In-Q-Tel and undisclosed others before adding $5m to close the round.
